Solid Biosciences (SLDB) Liabilities and Shareholders Equity (2017 - 2026)

Solid Biosciences has disclosed Liabilities and Shareholders Equity across 10 years of filings, most recently posting $422.9 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $422.9 million, up 22.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 26.89% YoY), and the FY2025 annual result was $232.5 million, up 23.26% from the prior year.
• Liabilities and Shareholders Equity came in at $422.9 million for Q1 2026 at Solid Biosciences, up from $232.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $422.9 million in Q1 2026 to a low of $164.9 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $229.6 million (2023), against an average of $241.6 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 36.62% in 2023 and jumped 38.29% in 2025, its largest moves.
• Solid Biosciences' Liabilities and Shareholders Equity stood at $260.3 million in 2022, then slumped by 36.62% to $164.9 million in 2023, then grew by 14.38% to $188.7 million in 2024, then climbed by 23.26% to $232.5 million in 2025, then jumped by 81.86% to $422.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $422.9 million (Q1 2026), $232.5 million (Q4 2025), and $273.9 million (Q3 2025), per Business Quant data.